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Abstract
Background Although the biological characteristics of uterine fibroids (UF) have implications for therapy choice and effec-
tiveness, there is limited MRI data about these characteristics. Currently, the Funaki classification and Scaled Signal Intensity 
(SSI) are used to predict treatment outcome but both screening-tools appear to be suboptimal. Therefore, multiparametric 
and quantitative MRI was studied to evaluate various biological characteristics of UF.
Methods 87 patients with UF underwent an MRI-examination. Differences between UF tissues and myometrium were 
investigated using T2-mapping, Apparent Diffusion Coefficient (ADC) maps with different b-value combinations, contrast-
enhanced T1-weighted and T2-weighted imaging. Additionally, the Funaki classification and SSI were calculated.
Results Significant differences between myometrium and UF tissue in T2-mapping (p = 0.001), long-TE ADC low b-values 
(p = 0.002), ADC all b-values (p < 0.001) and high b-values (p < 0.001) were found. Significant differences between Funaki 
type 3 versus type 1 and 2 were observed in SSI (p < 0.001) and T2-values (p < 0.001). Significant correlations were found 
between SSI and T2-mapping (p < 0.001; ρs = 0.82), ADC all b-values (p = 0.004; ρs = 0.31), ADC high b-values (p < 0.001; 
ρs = 0.44) and long-TE ADC low b-values (p = 0.004; ρs = 0.31).
Conclusions Quantitative MR-data allowed us to distinguish UF tissue from myometrium and to discriminate different UF 
tissue types and may, therefore, be a useful tool to predict treatment outcome/determine optimal treatment modality.
Keywords Uterine fibroids · High-intensity focused ultrasound ablation · Magnetic resonance imaging · Diffusion MRI
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DWI  Diffusion-weighted imaging
MR-HIFU  Magnetic resonance image guided-high inten-
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TE  Echo time
tSSS  Transformed symptom severity score
tHRQL  Transformed health-related quality of life
UAE  Uterine artery embolization
UFS-QoL  Uterine fibroid symptom health-related qual-
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Introduction
Uterine fibroids (UF) are the most common benign smooth 
muscle cell tumors in the pelvic area among women. It is 
estimated that up to 70% of women develop UF during their 
fertile life [1]. Black women have the highest risk to develop 
UF. Hormone concentrations, growth factors and increased 
angiogenesis are thought to play an important role in the 
formation and growth of UF [2, 3]. The use of oral contra-
ceptives and high parity tend to lower the risk [4]. Approxi-
mately 25% of women with UF suffer from symptoms [5]. 
UF are associated with a high morbidity and may lead to 
career delay [4]. The main symptoms can be classified into 
three categories: heavy or prolonged menstrual bleeding, 
bulk-related symptoms or reproductive dysfunction and 
obstetric difficulties [6]. Symptoms can be assessed using 
the Uterine Fibroid Symptom-Quality of Life questionnaire 
(UFS-QoL), a validated disease-specific questionnaire 
including questions about symptom severity (transformed 
Symptom Severity Score; tSSS) and Quality of Life (QoL) 
(transformed Health-Related Quality of Life; tHRQL) [7].
Women suffering from symptomatic UF most commonly 
start with (hormonal) medication. When this is ineffective, 
more invasive treatment options such as the surgical inter-
ventions myomectomy or hysterectomy, are considered. 
Hysterectomy is the most frequently performed gyneco-
logical procedure worldwide, with UF being its most 
important indication [8, 9]. Less invasive treatment options 
include Uterine Artery Embolization (UAE) and Magnetic 
Resonance-guided High-Intensity Focused Ultrasound 
(MR-HIFU) [10]. MR-HIFU is a non-invasive therapeutic 
modality which combines image guidance, using Magnetic 
Resonance Imaging (MRI), with a therapeutic High-Inten-
sity Focused Ultrasound (HIFU) transducer [8].
Because not all fibroids are suitable for a minimally 
invasive fibroid therapy, an MRI is often performed to 
assess a patients’ eligibility [11, 12]. However, there is 
limited data about biological characteristics of uterine 
fibroids (UF) on the histological level and on MR imaging. 
Based on what is known about the histopathology, multi-
ple subtypes of uterine fibroids are recognized [13]. Uter-
ine fibroids are composed of smooth muscle fiber bundles, 
surrounded by collagenous fibrous connective tissue con-
taining blood vessels. Also different types of mast cells are 
present. The density of each of these cell types is different 
for the various types of uterine fibroids. Because of these 
differences, fibroids react differently on thermal ablation. 
At this moment, there are no perfect imaging classifiers 
available to predict treatment outcome or to determine the 
optimal treatment modality for the individual patient.
The most commonly used classification system to pre-
dict the ultrasonic heating efficacy of UF is the Funaki 
classification. The Funaki classification divides fibroids 
into three subgroups based on the Signal Intensity (SI) of 
UF on T2-weighted (T2w) MR images compared to the SI 
of muscle and myometrium [14, 15]. Funaki type 3 fibroids 
can be unresponsive to MR-HIFU therapy, so are gener-
ally considered ineligible [12]. Funaki type 1 fibroids are 
expected to be good candidates for MR-HIFU treatment 
whereas almost all Funaki type 2 can be treated success-
fully [14], but varying treatment results have been reported 
[16, 17]. This inaccuracy hampers the potential impact of 
MR HIFU treatment in UF patients. Therefore, the search 
for more discriminative parameters has started and further 
explorative research about biological characteristics of UF 
on MRI is needed.
To select patients for UAE, Kang et al. defined another 
screening tool based on T2w images, the so called Scaled 
Signal Intensity [18, 19]. In contrast to the Funaki clas-
sification, the SSI score has a continuous numeric scale, 
and may, therefore, be more appropriate for screening 
when using a multiparametric MRI approach. To calcu-
late the SSI the SI of a UF is scaled between 0 and 100 
using the intensities of the rectus abdominis muscle and 
of subcutaneous fat as the minimum and maximum refer-
ence values for the scale, respectively. UF with a high SI 
on T2WI are more suitable for UAE. The SSI cutoff value 
to predict a volume reduction rate  >  50% after UAE was 
reported to be  >  18.16 [19]. Park et al. [18] observed a 
correlation between SSI and MR-HIFU treatment result, 
e.g. the non-perfused volume (NPV) percentage. The SSI 
cutoff value to predict NPV  >  45% was  <  16.0, thus MR-
HIFU is more effective in UF with a low SI on T2WI [18, 
19]. This difference between MR-HIFU and UAE might 
be due to the fact that fibroids with a high SI on T2WI are 
histopathologically correlated with high vascularity and 
proliferative activity which are both associated with a poor 
MR-HIFU treatment outcome.
In the past other, more quantitative, approaches have 
been explored to improve the screening of patients leading 
to improved therapy outcomes of MR-HIFU ablation of UFs.
A quantitative parameter that could be of interest for 
screening is the transverse relaxation time of the tissue (T2), 
which can be mapped using a T2-mapping pulse sequence 
with appropriate post-processing. Compared to T2w scans, 
T2-mapping has the benefit of being more independent of 
MRI settings and hardware imperfections [20], and does not 
require a reference tissue. Therefore, T2-mapping could be 
more useful for classification. It is expected that the val-
ues of the T2 relaxation time will reflect relevant UF tissue 
properties, in particular blood volume and interstitial fluid 
volume. Histopathologically, UF with a long T2 relaxation 
time are correlated with higher water content, e.g. interstitial 
fluid or blood volume. These features are both associated 
with poor therapeutic efficacy of MR-HIFU. Additionally, 
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it is difficult to elevate the temperature in high perfused tis-
sues [12].
In the current study, we also evaluated different combina-
tions of b-values to investigate if the characterization of UF 
tissue can be refined by adding information obtained from 
the apparent diffusion coefficient (ADC) maps. Andrews 
et al. [29] reported that Funaki type 3 fibroids have higher 
ADC values compared to Funaki type 1 and 2 fibroids, 
which is indicative of increased extracellular water content 
and/or blood volume. Ikink et al. [21] have demonstrated 
that the ADC in fibroid tissue is influenced by the choice of 
b-values and can contain information about the diffusion as 
well as the perfusion/blood volume in the UF. A significant 
decrease was seen in ADC values with the lowest b-values (0 
and 200) between the ablated UF volume pre and post MR-
HIFU treatment. An explanation for these observations may 
be that the ADC acquired for low b-values strongly reflects 
perfusion effects, i.e. the micro-circulation of blood in the 
capillaries of the UF [21]. Moreover, Funaki type 3 fibroids 
demonstrate a higher pseudo diffusion coefficient compared 
to type 1 and 2 which could be related to higher vascularity 
[29]. Therefore, ADC might be useful to characterize UF 
tissue and to be able to distinguish between the different 
UF subtypes.
To possibly further characterize UF tissues, long-echo 
time (TE) ADC using low b-values was also investigated to 
emphasize not only the low blood perfusion but also the T2 
relaxation time. The amount of water is also expected to be 
different between leiomyoma subtypes. Therefore, a better 
characterization of UF tissues could be provided by setting 
a longer echo time for the acquisition.
Materials and methods
This single-center, prospective, explorative study was per-
formed at the Gynecology and Radiology departments of 
Isala Hospital, Zwolle, the Netherlands. This study was 
approved by the local ethics committee (registration number 
NL53499.075.15) and the hospital Board.
Patients
All patients presenting with UF symptoms at the gynecol-
ogy outpatient clinic between December 2015 and June 
2017 were evaluated for inclusion. Inclusion criteria were: 
UF confirmed on ultrasound, age over 18 years and pre- or 
peri-menopausal state. Exclusion criteria were: pregnancy, 
calcification of the UF, severe obesity or MRI contra-indi-
cations including contrast allergy. All eligible patients with 
symptomatic UF were offered to undergo an MRI exami-
nation regardless of their interest in MR-HIFU treatment. 
Potentially eligible patients for MR-HIFU therapy were 
counseled after the MRI. Results of the MR-HIFU treat-
ments and post-treatment evaluation will be reported in a 
future paper. Informed consent was obtained before the MRI 
or filling out the UFS-QoL questionnaire. The tSSS and the 
tHRQL were calculated from the UFS-QoL questionnaire 
resulting in a scoring range between 0 and 100; higher scores 
indicate greater symptom severity or better QoL. Spies et al. 
[22] reported that fibroid patients at baseline scored 64.8 
for the tSSS and 40.8 for the tHRQL and that the normal 
control group scored 15.3 for the tSSS and 92.8 for the 
tHRQL. Patient (age and ethnicity) and UF (number of UF, 
fibroid volume and location) characteristics were compared 
between the three Funaki types and related to outcomes of 
the UFS-QoL.
Imaging protocol
MRI scans were performed on a clinical 1.5-T MRI sys-
tem (Achieva; Philips Healthcare, Best, the Netherlands). 
Patients were scanned in prone position. Sequence parameter 
settings are listed in Table 1. The examination was started 
with a survey followed by a sagittal T2w multishot Turbo 
Spin Echo (TSE) (TSE factor 17; TE 125 ms) and an axial 
T2w multishot TSE (TSE factor 18; TE 110 ms) to identify 
anatomical structures within the pelvis. After administra-
tion of a contrast agent  (DOTAREM®, 0.2 mL/kg; Gadoter-
ate Meglumine, 0.1 mmol/kg; Guerbet; Aulnay-sous-Bois, 
France) three-dimensional (3D) T1-weighted (T1W) spoiled 
gradient echo (FFE) images were obtained (Table 1). Con-
trast-Enhanced (CE) images were used to assess the viabil-
ity of the UF. Furthermore, the study protocol consisted of 
short-TE (64 ms) DWI and long-TE (140 ms) DWI series 
using a fat-suppressed multi-slice single-shot spin echo-echo 
planar imaging (SE-EPI) sequence (Table 1). To reduce the 
scan time, the multi-slice multi-echo sequence, T2-mapping, 
was performed using a multishot gradient and spin echo 
(GRASE) sequence with fat-suppression (Table 1). Twelve 
echoes were acquired, with TE ranging from 20-240 ms in 
20 ms increments. The quantitative imaging protocol was 
obtained before the contrast administration. The total acqui-
sition time of the MRI protocol was approximately 20 min.
Generation of parameter maps
T2-mapping: T2 maps were generated by voxel-wise fitting 
of a mono-exponential function to the pixel signal intensity 
S for the different TEs, with T2 and S0 as a fit parameter:
The first echo was omitted from the fit since it has a stimu-
lated echo component in it [23].
S
(
T
E
)
= S
0
× e
−TE∕T
2
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DWI DWI images were acquired with 7 b-values: 0, 
50, 100, 200, 400, 600 and 800 s/mm2. ADC maps from 
the DWI images were calculated by a voxelwise fit of a 
mono-exponential function to the pixel signal intensities 
(S) using the formula, with ADC and S0 as fit parameters:
Three different ADC maps were calculated. The first ADC 
map was reconstructed with all measured b-values, the sec-
ond ADC map with only the three lowest b-values (0, 50, 
100 s/mm2) and the third ADC map with only the three high 
b-values (400, 600, 800 s/mm2). Four different b-values (0, 
50, 100, 200 s/mm2) were acquired for the long-TE DWI 
sequence and the ADC map was derived using these low 
b-values.
S(b) = S0 × e
−b×ADC
Measurements
IntelliSpace Portal (ISP) software (version 8, Philips Health-
care, Best, The Netherlands) was used for calculating param-
eter maps and for the region-of-interest (ROI) analysis. In 
the case of multiple UFs, the largest UF was chosen for anal-
ysis. The total UF volume was measured by drawing a Vol-
ume Of Interest (VOI) on the T2w images using the tumor 
tracking application in ISP. A user-selected seed location 
was chosen at an initial slice, approximately in the center of 
the UF. Then, the system measured UF volume automati-
cally and the observer manually adapted the segmentation 
when necessary. The following ROI placement protocol 
(Fig. 1) was used to determine the Funaki classification and 
SSI: (1) all measurements were performed on the axial slice 
Table 1  The MRI protocol with relevant imaging parameter settings
DWI diffusion weighted imaging, TE echo time, TSE turbo spin echo, GRASE gradient and spin echo, EPI echo planar imaging, SE spin echo, 
FFE fast field echo, TFE turbo field echo, TR repetition time, ACQ acquired, FOV field of view, Scan% scan percentage, NSA number of signal 
averages, SPIR spectral presaturation inversion recovery, SPAIR spectral selection attenuated inversion recovery
T2w axial T2w sagittal T2-mapping DWI DWI long TE CE-T1w
Scan type TSE multishot
TSE factor 18
TSE multishot
TSE factor 17
GRASE multishot
TSE factor 12
EPI factor 5
Single shot SE-EPI
EPI factor 51
Single shot SE-EPI
EPI factor 51
3D FFE
TFE multishot
TFE factor 44
TE (ms) 110 125 n × 20 64 140 2.6
TR (ms) 3656 6219 2438 2673 6715 5.4
Flip angle (˚) 90 90 90 90 90 10
Slice thickness (mm) 3.5 3.0 7.0 7.0 7.0 3.0
ACQ Matrix 356 × 198 356 × 187 112 × 82 112 × 80 112 × 80 168 × 157
FOV (mm) 250 × 180 250 × 180 250 × 188 250 × 188 250 × 188 250 × 250
ACQ Voxel size (mm) 0.7 × 0.88 0.7 × 0.94 2.23 × 2.23 2.23 × 2.26 2.23 × 2.26 1.5 × 1.49
Scan% 77.3 73.0 98.2 95.6 95.6 94
NSA 2 3 2 4 4 3
Half scan No No No Yes Yes No
Fat suppression No No SPIR SPAIR SPAIR SPAIR
Scan duration (min:s) 2:48.2 3:31.5 2:55.5 6:51.6 4:35.3 2:31.2
Fig. 1  The ROI placement protocol used to determine the Funaki class and SSI of the uterine fibroid. All measurements were performed manu-
ally on the axial slice of the T2w series in 2D and were repeated three times. The ROI size was maximum while avoiding adjacent structures
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of the T2w series (TE 110 ms); (2) the circular ROI’s were 
manually drawn three times in 2D; (3) the median value 
was used for classification; (4) the ROI size was maximum 
while avoiding adjacent structures; (5) anatomical locations 
of the ROI’s were predefined, the UF tissue ROI  (SIfibroid) 
was placed approximately in the center, the muscle ROI in 
the rectus abdominis muscle  (SImuscle), the fat ROI in the 
subcutaneous abdominal fat  (SIfat) and the myometrium ROI 
 (SImyometrium) not close to the cervix, UF or endometrium.
After all ROI’s were drawn, the UF was classified as a 
Funaki type 1, 2 or 3 according to the following criteria: (1) 
SI equal to or lower than the SI of skeletal muscle; (2) SI 
higher than the SI of skeletal muscle, but lower than the SI 
of myometrium; (3) SI comparable to or higher than the SI 
of myometrium, respectively.
The SSI score was calculated with the following formula:
Finally, the SSI score was related to the Funaki classifica-
tion. Furthermore, since Funaki’s method does not pre-
scribe the amount of T2-weighting required, the currently 
used Funaki classification was reevaluated by comparing the 
Funaki distribution for T2w scans with four different echo 
times. All ROI’s were drawn on the T2w images with TE 
110 ms as well as on the T2w images with 125 ms and in 
the images of the corresponding echoes of the TSE sequence 
from the T2-mapping (TE 20 ms and 60 ms). Thus, each UF 
was classified four times. The Funaki distribution measured 
on 110 ms was used for analysis since this is the standard 
TE in our local MRI protocol.
All T2 and ADC maps were evaluated to distinguish UF 
tissue from myometrium. On these maps, ROI’s were placed 
in the UF (center) and the uterine myometrium on the axial 
slices. Firstly, the ROI’s were drawn on the T2 and then cop-
ied onto the ADC maps with different b-value combinations 
and different echo times. The conventional T2w scans were 
used as a visual reference for the identification of UF tissue 
and myometrium. The measured T2 and ADC values were 
compared between the three Funaki types and related to the 
SSI score of the UF.
Statistical analysis
To minimize random errors, all ROI measurements were 
performed three times by two observers. Per observer the 
median value was used for further analysis. To minimize 
the inter-observer variability, the ROI placement approach 
was standardized in the protocol as outlined above. All VOI, 
ROI data and mean values were stored in an Excel database 
(Microsoft). Statistical analyses were performed using IBM 
SSI =
SI
fibroid
− SI
muscle
SI
fat
− SI
muscle
× 100
SPSS version 25 and R, version 3.4.2, the R Foundation for 
Statistical Computing. Categorical data were presented as n 
(%). Continuous variables were presented as mean (± SD) 
in the case of a normal distribution, in the case of a skewed 
distribution the median (Q1–Q3) values were also reported. 
Distribution was assessed by the Shapiro–Wilk test, com-
plemented by plots and the indices skewness and kurtosis. 
Differences between MR-parameters of UF tissue and myo-
metrium were tested by means of the paired T-test or the 
Wilcoxon’s signed-rank test. Correlations between continu-
ous variables (SSI score, MR-parameters, tSSS, tHRQL, age, 
UF volume) were investigated using Pearson’s/Spearman’s 
correlation. Additionally, to investigate categorical inde-
pendent variables (Funaki classification and intra-uterine 
location of the UF) regression analysis was performed and 
dummy variables were used.
Results
In total, 87 women with symptomatic UF were included 
in this study (Table 2). All included patients underwent an 
MRI examination and a typical example of the acquired 
MR images are shown in Fig.  2. Median age was 46.0 
(42.0–49.0) years and the majority of the study participants 
were Dutch (73.6%). Most women had multiple UF (58.6%) 
with a median volume of 115.3 mL (31.2–248.3). Intramural 
location of the UF was frequent (56.3%) compared to a sub-
mucosal (21.8%) or subserosal location of the UF (21.8%).
Funaki
Overall, 66.7% of the UFs were classified as Funaki 2 
(5.7% as type 1 and 27.6% as type 3) when measured on 
the axial T2w images (TE 110 ms). The distributions of 
the UF over the three Funaki types differed for the four TE 
(20 ms, 60 ms, 110 ms and 125 ms) (Fig. 3). The shorter 
the echo time used to determine the Funaki classification 
the higher the percentage of Funaki type 3 fibroids. Moreo-
ver, no Funaki type 1 fibroids were found when the Funaki 
classification was based on a scan with TE 125 ms. Several 
significant differences were found in patient and fibroid char-
acteristics between the three Funaki types; the UF volume 
was significantly higher (p = 0.022) in the Funaki type 3 
group (mean: 244.51 mL) compared to the Funaki type 2 
(mean: 143.14 mL). The number of UFs was significantly 
higher (p = 0.032) in the group of patients with Funaki type 1 
fibroids (60.00% had more than 5 fibroids) than the patients 
in the Funaki type 3 group (58.33% had only 1 UF).
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SSI
The average measured SSI-score was 12.7 (6.3–25.1). 
A significant difference was seen between Funaki type 3 
compared to Funaki type 2 (p < 0.001) or Funaki type 1 
(p < 0.001) and also between Funaki type 1 and Funaki type 
2 fibroids (p = 0.001).
Quantitative parameters
Significant differences were found between the normal uter-
ine myometrium and UF tissue for the measured T2 values, 
the long-TE ADC map with low b-values and two of the 
three ADC maps, namely, the map derived from all b-values 
and the map derived from only high b-values (Table 3). The 
ADC maps obtained with low b-values did not show a sig-
nificant difference between UF and myometrium.
A significant difference in observed T2 values was seen 
between Funaki type 3 versus 1 (p < 0.001) or 2 (p < 0.001) 
and Funaki type 2 versus 1 (p = 0.005). The long-TE ADC 
with low b-values resulted in a significant difference between 
Funaki type 1 compared to Funaki type 2 (p = 0.016) and 
type 3 (p = 0.006). Moreover, significant differences were 
also observed in the ADC with all b-values (p = 0.029) and 
ADC with high b-values (p = 0.025) between Funaki type 3 
versus Funaki type 2.
The SSI and quantitative MR-parameters showed sig-
nificant correlations between the SSI and T2-mapping 
(p < 0.001; ρs = 0.82), ADC with all b-values (p = 0.004; 
ρs = 0.31), ADC with only high b-values (p < 0.001; 
ρs = 0.44) and long-TE ADC with low b-values (p = 0.004; 
ρs = 0.31).
Significant differences were found between the three 
Funaki types in SSI, ADC values and T2-mapping values. 
To possibly demonstrate these differences, the distribution 
of the three Funaki types for these MR-parameters is visual-
ized in Fig. 4.
UFS‑QoL
Patients had an average tSSS of 49.1 ± 21.0 before the MRI 
examination and an average tHRQL of 57.0 ± 23.9 (Table 2). 
As expected, the tSSS and tHRQL were strongly correlated 
(p < 0.001; r = − 0.81). The tSSS showed significant dif-
ferences between Funaki type 3 compared to Funaki type 
2 (p < 0.001) and Funaki type 1 (p = 0.040) (Fig. 5). The 
tHRQL showed a significant difference (p < 0.001) between 
Funaki type 3 compared to Funaki type 2 (Fig. 5). Moreover, 
the tSSS was significantly different for ethnicity (p = 0.030) 
and intra-uterine location of the UF; tSSS was significantly 
different for subserosal located UF compared with intra-
mural (p = 0.002) and submucosal UF (p = 0.001). Subse-
quently, the tHRQL was also significantly different for eth-
nicity (p = 0.015) and the location of the UF; tHRQL was 
significantly different for subserosal located UF compared 
with intramural (p = 0.005) and submucosal UF (p = 0.001).
Discussion
In this study, an unselected patient population with UF 
underwent a multiparametric MRI examination to investi-
gate differences between fibroid tissue types in T2 and ADC 
values and to compare the SSI score, patient characteris-
tics and scores of the UFS-QoL between the three different 
Funaki types. We will discuss the investigated potentially 
discriminating parameters in detail below.
The three Funaki types showed differences in UF volume, 
indicating that Funaki type 3 fibroids are in general larger. 
Funaki type 1 fibroids are not only smaller on average, but 
Table 2  Patient characteristics
a Median (interquartile range) and mean ± standard deviation
b n (%)
c Scaled signal intensity
d Mean ± standard deviation
e Transformed symptom severity score
f Transformed health-related quality of life
Characteristic
Age (years)a 46.0 (42.0–49.0)
45.6 ± 5.4
Number of  fibroidsb
 1 36 (41.4)
 2 14 (16.1)
 3 15 (17.2)
 4 4 (4.6)
 5 or more 18 (20.7)
Fibroid  locationb
 Submucosal 19 (21.8)
 Intramural 49 (56.3)
 Subserosal 19 (21.8)
Fibroid volume (mL)a 115.3 (31.2–248.3)
171.5 ± 182.0
Funaki  classificationb
 1 5 (5.7)
 2 58 (66.7)
 3 24 (27.6)
SSIa,c 12.7 (6.3–25.1)
16.91 ± 13.19
tSSSd,e 49.1 ± 21.0
tHRQLc,c 57.0 ± 23.9
Dutch  ethnicityb
 Yes 64 (73.6)
 No 23 (26.4)
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patients with Funaki type 1 fibroid also develop more UF 
compared to other Funaki types [24].
Importantly, Funaki and colleagues did not specify 
the scan protocol settings for the T2w images in the MRI 
protocol which they advised to use for their Funaki clas-
sification of UF. To investigate the effect of the strength of 
T2 weighting on the Funaki classification, we used differ-
ent TE’s in the T2w scans used to determine Funaki type. 
Fig. 2  Images of all the different MR-parameters used in the MRI 
protocol of this study. The purple dot represents the middle of the 
uterine fibroid. On the two left upper images, a single intramural 
uterine fibroid is shown with distortion of the uterine cavity. The 
signal intensity of the fibroid is lower than the uterine myometrium, 
but higher than the rectus abdominis muscle, so this is a Funaki type 
2 fibroid. After administration of gadolinium on the T1-weighted 
image, there is homogeneous enhancement of the uterine fibroid 
which is less than the enhancement of the uterine wall (myometrium). 
The derived T2 map is shown on the right upper image. The recon-
structed ADC maps with different combinations of b-values are dem-
onstrated in the lower part of the image
Fig. 3  Barplot showing distri-
bution of patients over the three 
Funaki types on T2-weighted 
images with four different 
echo times (TE). The number 
of patients is shown on the 
Y-axis and the Funaki classifi-
cation on the X-axis. The four 
different echo times (20 ms, 
60 ms, 110 ms and 125 ms) are 
indicated by different colors
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The distribution of the Funaki classification was differ-
ent depending on the echo time used which is important 
to realize. When using the 20 ms and 60 ms T2w images, 
more fibroids were classified as a Funaki type 3. This can 
be explained by the fact that the SI of myometrium and UF 
tissue on T2w images is more similar when the TE is shorter. 
In addition, the MRI scan must be of good diagnostic quality 
to evaluate anatomy and to detect incidental findings. There-
fore, the T2w images with a TE of 20 ms or 60 ms are not 
applicable for screening. When using a TE of 125 ms, we did 
not find any Funaki type 1 fibroids. This can be explained by 
the fact that fibroids contain more water (in particular blood 
volume) than muscle, so the SI of muscle on T2w images 
with TE of 125 ms is lower than the SI of UF. Moreover, 
less Funaki type 3 fibroids were seen with TE 125 ms and 
more Funaki type 2 fibroid than with the other TE setting. 
The Funaki distribution seen at T2w images with 125 ms 
might lead to a higher treatment failure rate due to allocation 
of UF to the Funaki type 2 group instead of Funaki type 3 
group since it is known that treatment failures still occur in 
the Funaki type 2 group [17, 25]. The true clinical impact 
of these findings should be investigated in the future, but it 
should be noted that the TE in the MRI protocol for T2w 
images greatly influences the distribution of the different 
Funaki groups. Furthermore, a standardized approach for 
the ROI-based measurements to determine Funaki has not 
been established yet. We propose a standardized ROI place-
ment approach as described in our methods section because 
random measurements are prone to selection bias. In clini-
cal practice, to determine the Funaki class of a UF is often 
performed by subjective visual assessment of the radiologist 
with an even higher risk for inaccuracy. Due to the hetero-
geneity of the SI of the UF on T2w images, a UF could be 
allocated to the Funaki type 2 group instead of the Funaki 
type 3 group.
Our findings provide additional insights into the subopti-
mal nature of the Funaki classification as a discriminator and 
tissue characterization is further limited because only three 
subclasses exist. The SSI, on the other hand, is a numeric 
variable and thus may be a more suitable tool for patient 
Table 3  Comparison of the 
observed T2 values and the 
ADC values  (10–3 mm2/s) 
calculated with different 
combinations of b-values 
between uterine fibroids and 
myometrium
a Median (interquartile range)
b Calculated using the Wilcoxon Signed Rank Test
c Mean ± standard deviation
d Calculated using the paired t-test
Uterine fibroid Myometrium p value
T2-mappinga 70.60 (58.70–84.50) 78.30 (69.30–86.40) 0.001b
b-values 0, 50, 100, 200, 400, 600,  800c 1.21 ± 0.24 1.39 ± 0.25  < 0.001d
b-values 0, 50,  100c 3.18 ± 0.84 3.39 ± 1.01 0.110d
b-values 400, 600,  800a 1.00 (0.90–1.10) 1.10 (1.00–1.20)  < 0.001b
Long-TE ADC b-values 0, 50, 100,  200c 2.49 ± 0.66 2.88 ± 0.93 0.002d
Fig. 4  Pairs plot for correlation 
of descriptive variables and 
Scaled Signal Intensity (SSI) 
split by Funaki classification. 
Pairs plot is a combination of 
scatter plots, density functions 
and correlation for each Funaki 
Class. The different Funaki 
groups are shown by different 
colors. On the Y-axis, the vari-
ables are the T2-mapping val-
ues, the ADC with all b-values 
and the SSI
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selection when using a multiparametric MRI approach. Park 
et al. [18] noted that patients with a SSI-score of 16 or below 
had the highest change of an NPV > 45% after MR-HIFU 
treatment. When the SSI classification system described by 
Park et al. would have been used to determine suitability for 
MR-HIFU, only 52 patients would have been eligible. When 
considering Funaki type 1 and 2 eligible for treatment, 63 of 
our 87 patients would have been suitable for MR-HIFU treat-
ment [14]. When Funaki classification is used, more patients 
are eligible for MR-HIFU compared to SSI.
Significant differences between myometrium and UF tis-
sue were found in all the parametric MR images, except 
the ADC with low b-values. The T2 value in the UF was 
considerably lower than the T2 value of the myometrium, 
presumably due to less hydration of UF tissue compared to 
myometrium [26]. This finding corresponds with the find-
ing that the ADC values are higher for myometrium than 
UF tissue. However, the ADC map with low b-values is not 
useful in differentiating between UF tissue and myometrium 
indicating that diffusion/perfusion characteristics of myome-
trium and UF tissue were similar. Ikink et al. [21] suggested 
that ADC maps obtained with only low b-values emphasizes 
the perfusion contribution to the ADC.
To differentiate UF types based on their diffusion/per-
fusion characteristics rather than on T2w images only, 
correlations with the SSI and Funaki classification were 
investigated. From all the combinations of ADC maps with 
different b-values, only the ADC map with the low b-values 
did not correlate with SSI. This could be explained by the 
fact the ADC map with low b-values reflects tissue perfusion 
[21], and movement of water molecules is not detected with 
T2w imaging on which the SSI is measured. The Funaki type 
3 UF showed a higher long-TE ADC value than a Funaki 
type 1, this could be expected since Funaki type 3 fibroids 
have a higher vascularity and an atypical Funaki type 3 UF 
could mimic leiomyosarcoma. Long-TE DWI can also be 
used to differentiate between malignant (high vascularity) 
and benign lesions, as demonstrated in previous studies, thus 
it might be a helpful screening tool to differentiate between 
UF tissues [27, 28]. Furthermore, significant differences 
were also seen between the Funaki classification and the 
ADC high b-values and ADC all-values. The finding that 
Funaki differs with the ADC map with all b-values is in line 
with Andrews et al. [29] who also suggested that Funaki type 
3 fibroids exhibit higher ADC values than Funaki type 1 and 
2, which implies increased extracellular water content and/
or blood volume in Funaki type 3 fibroids.
Quantitative T2-mapping was used to quantify UF tis-
sue properties, in particular water content (including blood). 
Significant differences were found in observed T2 values 
between the three Funaki types and a strong correlation was 
found between the T2-mapping and SSI. Since all measure-
ments are based on T2w images these findings were to be 
expected. The findings in this study may indicate that both 
SSI and T2-mapping are useful parameters for the evaluation 
of UF tissue imaging features. The accuracy of the Funaki 
classification system is not sufficient to predict MR-HIFU 
treatment outcome [30]. A perfect classifier would correctly 
Fig. 5  Barplot demonstrating the relationship between the Uter-
ine Fibroid Symptom-Quality of life (UFS-QoL) questionnaire. The 
Funaki classification is shown on the categorical X-axis with the 
UFS-QoL on the dual Y-axes. The transformed Symptom Severity 
Score on the left Y-axis is depicted with green bars, the right Y-axis 
and red line represent the transformed Health-Related Quality of Life. 
Data are presented in mean for each Funaki category including error 
bars (95% CI)
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select treatable fibroids only based on their MR character-
istics. Presumably, a multiparametric analysis would pro-
vide a more reliable prediction model for MR-HIFU treat-
ment outcome. To optimize patient selection for MR-HIFU 
therapy, the screening SSI and T2-mapping values of the 
UF should be linked to treatment parameters to determine 
a cut-off value (as part of a prediction model). A previous 
study already suggested that T2-mapping could be the most 
valuable parameter for treatment outcome [31].
In general, patients with a lower tSSS had a higher 
tHRQL as expected [7]. Interestingly, tSSS outcomes of 
patients with Funaki type 3 UF were significantly higher 
than tSSS values of patients with Funaki type 1 and type 
2 UF. In parallel, the tHRQL was significantly lower in 
patients with a Funaki type 3 UF compared to patients with 
a Funaki type 1 or 2 UF. One could argue that Funaki type 3 
fibroids generally grow faster due to their hypervascularity 
which could lead to a more immediate onset of symptoms 
and, therefore, impact on UFS-QoL questionnaire which 
only considers symptoms during the previous 3 months [7]. 
Moreover, as mentioned earlier the UF volume is also higher 
compared to that of Funaki type 1 and type 2 UFs, which 
contributes to the tSSS. Furthermore, Dutch patients had a 
lower tSSS and an improved tHRQL compared to women 
with different ethnicity. This may be explained by cultural 
differences in self-perception [9]. A submucosal location of 
the UF increased the tSSS and lowered the QoL. This out-
come is not surprising since a submucosal location of a UF 
leads to heavier bleeding and the tSSS part of the UFS-QoL 
questionnaire consists of eight questions in total from which 
four questions are related to bleeding symptoms.
A strength of this study was that an unselected patient 
population of women suffering from UF was included in 
this study independent of interest in MR-HIFU treatment. 
This led to a heterogeneous UF patient population, reduc-
ing the risk of selection bias. Furthermore, to the best of 
our knowledge this is the first in vivo study to investigate 
the imaging features of the total UF patient population and 
associate these UF characteristics with patient character-
istics, symptom severity and QoL. However, the skewed 
distribution of the patients in the Funaki classification 
together with the small sample size of the study resulted 
in statistical difficulties and, therefore, the outcomes of 
the Funaki type 1 group should be interpreted with cau-
tion. The skewed distributions are most likely explained 
by the fact that some leiomyoma histological variants are 
more common than other subtypes [13]. We were una-
ble to compare our findings with histology data because 
biopsies are not routinely performed to confirm the diag-
nosis of UF. Due to the explorative nature of this study, 
it seemed unethical to obtain pathological data, although 
future research to compare pre-treatment MR imaging 
with post-hysterectomy data would be valuable. Another 
limitation of this study was that the quality of some of the 
images was rather poor due to extrinsic (bowel or patient 
movement) reasons. Motion artefacts in the images made 
it more complicated to draw the ROI precisely. All ROI 
measurements were performed three times per observer for 
each tissue to minimize ROI placement errors. Often an 
outlier was seen in one of the ROI measurements and this 
outlier was eliminated using the median value for analysis. 
Furthermore, when performing the ROI measurements, it 
was difficult to standardize the measurement of the uter-
ine myometrium since the location of the UF influenced 
where the ROI in the myometrium could be placed. No 
agreements could be made in advance about the specific 
location for the ROI placement in the myometrium.
Further cluster analysis using a larger sample size (with 
a larger Funaki type 1 group) could reveal if a more objec-
tive way than the Funaki classification can be found to 
refine the characterization of UF. Moreover, to optimize 
patient selection for minimally-invasive treatment options 
of UF the predictive value of the quantitative MR-param-
eters should be correlated to treatment outcome such as 
NPV% and clinical follow-up.
Conclusions
This study showed that quantitative multiparametric MRI 
can differentiate between myometrium and UF tissue in 
an unselected patient population with symptomatic UF. 
Between different UF tissues, a large variation in mor-
phologic characteristics was found with the quantitative 
MR-parameters. The SSI and T2-mapping values appeared 
to be useful parameters for the evaluation of UF tissue 
imaging features, however, these results should be linked 
to treatment outcome.
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